GlycoMimetics Inc
(NAS:GLYC)
$
0.3131
-0.0079 (-2.46%)
Market Cap: 20.19 Mil
Enterprise Value: 6.06 Mil
PE Ratio: 0
PB Ratio: 1.78
GF Score: 30/100 GlycoMimetics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019 / 05:35PM GMT
Release Date Price:
$4.6
(+9.52%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome, everyone, to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. Before we start, please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk. For this session, we have Rachel King, CEO of GlycoMimetics. Welcome.
Rachel K. King
GlycoMimetics, Inc. - President, CEO & Director
Thank you. Glad to be here.
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
For those in the room who may not be familiar with GlycoMimetics, can you provide a brief introduction?
Rachel K. King
GlycoMimetics, Inc. - President, CEO & Director
Sure. So we have 2 clinical trials right now going on with our
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot